TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04529356
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
Study: NCT00645450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly doses of placebo (inactive pill) following recollection of traumatic memory
Study: NCT02654717
Drug: DFD-07 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02654717
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00529607
Drug: contrast echocardiography
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: directly after PCI, at 24 h after PCI, before discharge and at 6 months
Study: NCT03658876
Drug: Iron Sucrose Solution for Injection
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg iron sucrose given on 5 successive haemodialysis sessions
Study: NCT00680641
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg of Simvastatin once daily
Study: NCT00680641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg of placebo once daily
Study: NCT03007004
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
Study: NCT02711917
Drug: MAC 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 MAC Sevoflurane
Study: NCT02711917
Drug: MAC 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 MAC Sevoflurane
Study: NCT02711917
Drug: MAC 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 MAC Sevoflurane
Study: NCT04215965
Drug: Biphozyl (dialysate and replacement)
Normalized name: piperazine, 1-(4'-methoxy(1,1'-biphenyl)-2-yl)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
Study: NCT04215965
Drug: Prismocal B22 (dialysate) + phoxilium (replacement)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution with phosphate and calcium in CRRT with citratre-based antigoagulation
Study: NCT02889367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
Study: NCT04679415
Drug: hzVSF-v13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
Study: NCT03137069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered orally, as per the dosing schedules described above.
Study: NCT00003652
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03786783
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03786783
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01460511
Drug: Placebo-HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
Study: NCT02711267
Drug: 5% Zovirax® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Study: NCT02711267
Drug: 5% Aciclostad cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: (STADA Arzneimittel GmbH, Vienna, Austria)
Study: NCT00136565
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m², D1, 4 cycles
Study: NCT02711267
Drug: 5% Aciclovir cream 1A Pharma
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1A Pharma GmbH, Vienna, Austria)
Study: NCT02711267
Drug: 5% Zovirax Cold Sore Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: (GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
Study: NCT02711267
Drug: 5% Zovirax® cream (Austria)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (GlaxoSmithKline Pharma GmbH, Vienna, Austria)
Study: NCT00250198
Drug: STA-5326
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00136565
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/m², D1, 4 cycles
Study: NCT00447265
Drug: Lupus Treatment- Standard of Care
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
Study: NCT00447265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00910065
Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
Study: NCT00910065
Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
Study: NCT00910065
Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
Study: NCT02060526
Drug: Recombinant human heparan N-sulfatase [rhHNS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human heparan N-sulfatase \[rhHNS\]
Study: NCT01607580
Drug: low-dose glucocorticoid Methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients receive low-dose glucocorticoid from day 5 post transplant
Study: NCT02342574
Drug: F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of active compound
Study: NCT02342574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo
Study: NCT03949634
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Study: NCT01612988
Drug: BOMP
Normalized name: Bleomycin, Oncovin (vincristine), Methotrexate, and Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3
Study: NCT03414099
Drug: Ketum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
Study: NCT03414099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink matched for taste and appereance
Study: NCT03176953
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active medication
Study: NCT00446680
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo BD for 6 months
Study: NCT03504527
Drug: triple combinations
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Study: NCT00225810
Drug: Crohn's Disease
Normalized name: Humira Pen 40 MG/0.8 ML - Crohn's Disease Starter Pack
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03708354
Drug: placebo softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
Study: NCT00927914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03504527
Drug: double combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Study: NCT01456624
Drug: DW-ES(B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625mg
Study: NCT00086268
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00147368
Drug: intravenous (IV) arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02495636
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
Study: NCT03982134
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 is a humanized IgG4 antibody
Study: NCT00502411
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
Study: NCT02594995
Drug: NBP
Normalized name: Tri-N-Butyl Phosphate (TNBP)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03544567
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
Study: NCT02156271
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00391209
Drug: simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals,6 months
Study: NCT00391209
Drug: intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals, 6 months
Study: NCT04049409
Drug: CMAB809
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
Study: NCT03415139
Drug: Oral Glucose Tolerance Test (OGTT)
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
Study: NCT01774656
Drug: Pharmacological Treatment
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
Study: NCT01439776
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800IU/day
Study: NCT00337727
Drug: Comparator; Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 12mg Pbo tablets.
Study: NCT00337727
Drug: Comparator; Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg \& 125 mg Pbo capsules.
Study: NCT01965431
Drug: BI 207127 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04422899
Drug: AIV007
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal
Study: NCT03546868
Drug: [18F]FSPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
Study: NCT02730195
Drug: Tyrosine Kinase Inhibitor (TKI)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given TKI therapy
Study: NCT03354143
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
Study: NCT01795768
Drug: AZD 4547
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755573
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regime as described for pregabalin
Study: NCT02168569
Drug: Coartem™ (Artemether-lumefantrine combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
Study: NCT02168569
Drug: Coarsucam™ (Amodiaquine-artesunate combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
Study: NCT00107484
Drug: ferumoxtran-10
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02491944
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
Study: NCT02910583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules to match ibrutinib administered orally once daily
Study: NCT02491944
Drug: [14C]AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
Study: NCT00985920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
Study: NCT02785770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
Study: NCT01974739
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04172727
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
Study: NCT01759056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00505778
Drug: Mesalamine Twice-Daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
Study: NCT03414892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral
Study: NCT04250506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as tablets for oral use.
Study: NCT01857011
Drug: Intravenous Iron sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
Study: NCT01857011
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
Study: NCT01756651
Drug: Fentanyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of Intranasal fentanyl 100mcg vs 200 mcg.
Study: NCT02697344
Drug: R-(-)-Gossypol Acetic Acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04540016
Drug: [14C]HSK7653
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
Study: NCT03247452
Drug: Polyethylene Glycol plus ascorbic acid
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
Study: NCT00545272
Drug: short acting β2-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study: NCT00530621
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT00927004
Drug: Etoricoxib (Arcoxia)
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg, daily dose, oral delivery, 14 days duration
Study: NCT04028544
Drug: Qishenyiqi dropping pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
Study: NCT04028544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
Study: NCT03030976
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
Study: NCT02604849
Drug: Streptomycin
Normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00423501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc weekly
Study: NCT03486015
Drug: 30% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 30% glucose
Study: NCT01331005
Drug: nepafenac 0.1% drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop three times per day for one year
Study: NCT01074853
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT00903409
Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study: NCT02820324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02713074
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
Study: NCT04129437
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight based ibuprofen dosing
Study: NCT01311505
Drug: Myrin© 2 (Rifampicin + Isoniazid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
Study: NCT01737593
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02160054
Drug: Graceptor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01546623
Drug: TAP-144-SR(3M)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03288051
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
Study: NCT01806259
Drug: Ketorolac 30 mg IV
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug
Study: NCT01806259
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looking like the Active drug
Study: NCT00892801
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
Study: NCT01697930
Drug: [18F] 4-L-Fluoroglutamine (2S,4R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of \[18F\] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the \[18F\] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
Study: NCT02386735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days prednisone 40mg, two days placebo